| Elham M Ismail, MD | |
|
70 Cohansey St, Bridgeton, NJ 08302-1918 | |
| (856) 451-4700 | |
| (856) 863-5732 |
| Full Name | Elham M Ismail |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Location | 70 Cohansey St, Bridgeton, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225057276 | NPI | - | NPPES |
| 172369822 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 2267101 (New York) | Primary |
| Entity Name | Community Health Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700816816 PECOS PAC ID: 9335040419 Enrollment ID: O20040402000981 |
News Archive
YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.
Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.
Kaiser Health News reports that "employers struggling with the steady rise of health insurance costs - which in 2009 increased 5 percent to an average of $13,375 for family coverage - are passing on more of the expense to their workers through higher deductibles and co-payments, according to survey released today." The survey was by the Kaiser Family Foundation and the Health Research & Educational Trust (Galewitz and Villegas, 9/15).
Scientists in the Academy of Finland's Neuroscience Research Programme have reported promising new results with potential implications for the treatment of Parkinson's disease. They have been studying the impacts of nerve growth factors in the treatment of PD, and their latest results show that a certain growth factor can be used to halt the progress of damage brought on by a nerve poison and possibly even restore the function of damaged cells.
Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elham M Ismail, MD 53 S Laurel St, Second Floor, Bridgeton, NJ 08302-1946 Ph: (856) 451-4700 | Elham M Ismail, MD 70 Cohansey St, Bridgeton, NJ 08302-1918 Ph: (856) 451-4700 |
News Archive
YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.
Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.
Kaiser Health News reports that "employers struggling with the steady rise of health insurance costs - which in 2009 increased 5 percent to an average of $13,375 for family coverage - are passing on more of the expense to their workers through higher deductibles and co-payments, according to survey released today." The survey was by the Kaiser Family Foundation and the Health Research & Educational Trust (Galewitz and Villegas, 9/15).
Scientists in the Academy of Finland's Neuroscience Research Programme have reported promising new results with potential implications for the treatment of Parkinson's disease. They have been studying the impacts of nerve growth factors in the treatment of PD, and their latest results show that a certain growth factor can be used to halt the progress of damage brought on by a nerve poison and possibly even restore the function of damaged cells.
Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder.
› Verified 6 days ago
Christopher Struby, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 Laurel Heights Dr # 201, Bridgeton, NJ 08302 Phone: 856-455-4800 | |
Mr. Fiore J Copare, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 Laurel Heights Dr, Bridgeton, NJ 08302 Phone: 856-455-4800 Fax: 856-453-1450 | |
Dr. Gladwyn D Baptist, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Magnolia Ave, Suite F, Bridgeton, NJ 08302 Phone: 856-455-2222 Fax: 856-455-6541 | |
Dr. John E Hatzantonis, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 Laurel Heights Dr, Bridgeton, NJ 08302 Phone: 856-455-4800 Fax: 856-453-1450 | |
Laila Dadvand, M.D., PH.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 201 Laurel Heights Dr, Bridgeton, NJ 08302 Phone: 856-455-4800 Fax: 856-451-0650 | |
Mr. Ilyas Ahmed, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 217 Laurel Heights Drive, Bridgeton, NJ 08302 Phone: 856-451-4150 Fax: 856-451-2645 |